Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
about
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyBody mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.PROLACTIN LEVELS IN PATIENTS WITH SCHIZOPHRENIA WHO WERE SWITCHED FROM DAILY TO ONCE-MONTHLY ARIPIPRAZOLE TREATMENT.
P2860
Q27320151-FF9EB201-9E99-4A4D-8DEE-BCFEAEA08DCFQ35100107-03D352BD-BB58-4B1D-A733-E9C9F13E0B7BQ35794615-906E9AC9-18E0-4DAA-809F-2305A926751BQ38233228-01D286E7-5DB1-434F-AC4E-2AFBBE10CAA1Q38570636-BDBB639D-0CC8-4CD3-BD24-34F72C6C6452Q38659006-9CEC3155-9D85-4846-96DB-BF7CDF7D4333Q39585148-DE4B8BD7-6663-4093-9596-32B8DF77A753Q47581504-77C96FF5-F9D3-4F3C-90E1-04C43839E44FQ47779069-C444DC8D-AE58-46E9-B6D6-DBD6A3F4F07EQ47998008-57D6F038-1D01-48E8-A584-06FE4B203318Q48004326-B3C0B273-38CF-491F-BDF8-2602B910CAFBQ51809943-48EB9875-08C3-4697-8250-C85E3FA19CC7Q53429141-11C1D3CA-D4B5-4FE2-BD45-0DCFD515697DQ55083271-F1E55C69-2C13-4DEB-B3CC-DA0493A48235
P2860
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-acting injectable paliper ...... led relapse prevention studies
@en
Long-acting injectable paliper ...... ed relapse prevention studies.
@nl
type
label
Long-acting injectable paliper ...... led relapse prevention studies
@en
Long-acting injectable paliper ...... ed relapse prevention studies.
@nl
prefLabel
Long-acting injectable paliper ...... led relapse prevention studies
@en
Long-acting injectable paliper ...... ed relapse prevention studies.
@nl
P2093
P2860
P356
P1476
Long-acting injectable paliper ...... led relapse prevention studies
@en
P2093
Bennett Levitan
Dong-Jing Fu
Ibrahim Turkoz
Larry Alphs
Michael Markowitz
Srihari Gopal
P2860
P2888
P356
10.1186/1744-859X-12-22
P577
2013-07-11T00:00:00Z
P6179
1019911008